Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Sun, Jianjun ^a,b   Xu, Jinbin ^a   Cairns, Nigel J ^a   Perlmutter, Joel S ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER H 3; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE H 3; DIHYDROTETRABENAZINE H 3; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; RACLOPRIDE H 3; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; WC 10 H 3;

AGED; AGING; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; EXTRASTRIATE BODY AREA; FEMALE; HAPLORHINI; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MALE; MATHEMATICAL MODEL; NONHUMAN; NUCLEUS ACCUMBENS; POSITRON EMISSION TOMOGRAPHY; PROTEIN ANALYSIS; PROTEIN BINDING; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR SENSITIVITY; THALAMUS; TISSUE DISTRIBUTION;

MACACA MULATTA;

EID: 84869768774     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049483     Document Type: Article

References (82)

1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, et al. (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104-8109.
2. Micheli F, Bonanomi G, Braggio S, Capelli AM, Celestini P, et al. (2008) New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems. Bioorg Med Chem Lett 18: 901-907.
3. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, et al. (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5: 25-43.
4. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, et al. (1990) Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147: 719-724.
5. Luedtke RR, Mach RH, (2003) Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Des 9: 643-671.
6. Neve KA, Seamans JK, Trantham-Davidson H, (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165-205.
7. Eiden LE, Schafer MK, Weihe E, Schutz B, (2004) The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 447: 636-640.
8. Ehrin E, Farde L, de Paulis T, Eriksson L, Greitz T, et al. (1985) Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot 36: 269-273.
9. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, et al. (1999) Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 26: 519-527.
10. Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, et al. (2006) High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry 59: 389-394.
11. Gurevich EV, Joyce JN, (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20: 60-80.
12. Hall H, Farde L, Halldin C, Hurd YL, Pauli S, et al. (1996) Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 23: 115-123.
13. Herroelen L, De Backer JP, Wilczak N, Flamez A, Vauquelin G, et al. (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 648: 222-228.
14. Hurley MJ, Jolkkonen J, Stubbs CM, Jenner P, Marsden CD, (1996) Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res 709: 259-264.
15. Lahti RA, Roberts RC, Tamminga CA, (1995) D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport 6: 2505-2512.
16. Murray AM, Ryoo H, Joyce JN, (1992) Visualization of dopamine D3-like receptors in human brain with [125I]epidepride. Eur J Pharmacol 227: 443-445.
17. Murray AM, Ryoo HL, Gurevich E, Joyce JN, (1994) Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A 91: 11271-11275.
18. Xu J, Hassanzadeh B, Chu W, Tu Z, Jones LA, et al. (2010) [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen. Synapse 64: 449-459.
19. Xu J, Chu W, Tu Z, Jones LA, Luedtke RR, et al. (2009) [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization. Synapse 63: 717-728.
20. Chu W, Tu Z, McElveen E, Xu J, Taylor M, et al. (2005) Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem 13: 77-87.
21. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K, (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112: 389-404.
22. Braak H, Braak E, Bohl J, Reintjes R, (1996) Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci Lett 210: 87-90.
23. Savasta M, Dubois A, Scatton B, (1986) Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res 375: 291-301.
24. Lim MM, Xu J, Holtzman DM, Mach RH, (2011) Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. Neuroreport 22: 489-493.
25. Novick A, Yaroslavsky I, Tejani-Butt S, (2008) Strain differences in the expression of dopamine D1 receptors in Wistar-Kyoto (WKY) and Wistar rats. Life Sci 83: 74-78.
26. Sibley DR, De Lean A, Creese I, (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem 257: 6351-6361.
27. Bancroft GN, Morgan KA, Flietstra RJ, Levant B, (1998) Binding of [3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology 18: 305-316.
28. Levesque D, Diaz J, Pilon C, Martres MP, Giros B, et al. (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A 89: 8155-8159.
29. Landwehrmeyer B, Mengod G, Palacios JM, (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 18: 187-192.
30. Morissette M, Goulet M, Grondin R, Blanchet P, Bedard PJ, et al. (1998) Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur J Neurosci 10: 2565-2573.
31. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, et al. (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15: 17-29.
32. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G, (1998) D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779: 58-74.
33. Gerfen CR, Surmeier DJ, (2011) Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34: 441-466.
34. Sanchez-Gonzalez JM, Rivera-Cisneros AE, Ramirez MJ, Tovar-Garcia JdeL, Portillo-Gallo J, et al. (2005) [Hydration status and aerobic capacity: effects on plasmatic volume during strenuous physical exercise]. Cir Cir 73: 287-295.
35. Rieck RW, Ansari MS, Whetsell WO Jr, Deutch AY, Kessler RM, (2004) Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies. Neuropsychopharmacology 29: 362-372.
36. Karasinska JM, George SR, Cheng R, O'Dowd BF, (2005) Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. Eur J Neurosci 22: 1741-1750.
37. Mukherjee J, Shi B, Christian BT, Chattopadhyay S, Narayanan TK, (2004) 11C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain. Bioorg Med Chem 12: 95-102.
38. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, et al. (2006) Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60: 485-495.
39. Olsson H, Halldin C, Swahn CG, Farde L, (1999) Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 19: 1164-1173.
40. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, et al. (2011) Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
41. Eisenstein SA, Koller JM, Piccirillo M, Kim A, Antenor-Dorsey JA, et al. (2012) Characterization of extrastriatal D2 in vivo specific binding of [(18) F](N-methyl)benperidol using PET. Synapse 66: 770-780.
42. Te Beek ET, de Boer P, Moerland M, Schmidt ME, Hoetjes NJ, et al. (2012) In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. J Psychopharmacol.
43. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, et al. (2006) D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85: 232-244.
44. Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, et al. (2010) Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 68: 634-641.
45. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, et al. (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65: 1024-1031.
46. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L, (2003) Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6: 361-370.
47. Volkow ND, Fowler JS, Wang GJ, (2002) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 13: 355-366.
48. Volkow ND, Wang GJ, Fowler JS, Logan J, Angrist B, et al. (1997) Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiatry 154: 50-55.
49. Carbon M, Niethammer M, Peng S, Raymond D, Dhawan V, et al. (2009) Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia. Neurology 72: 2097-2103.
50. Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, et al. (1997) Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 17: 843-850.
51. Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, et al. (1999) PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. Neuroimage 10: 666-674.
52. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, et al. (2012) Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32: 1353-1359.
53. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, et al. (2010) Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 13: 273-287.
54. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, et al. (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 63: 782-793.
55. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, et al. (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68: 392-399.
56. De Keyser J, Claeys A, De Backer JP, Ebinger G, Roels F, et al. (1988) Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 91: 142-147.
57. Mengod G, Villaro MT, Landwehrmeyer GB, Martinez-Mir MI, Niznik HB, et al. (1992) Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem Int 20 Suppl: 33S-43S.
58. Palacios JM, Camps M, Cortes R, Probst A, (1988) Mapping dopamine receptors in the human brain. J Neural Transm Suppl 27: 227-235.
59. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, et al. (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74: 59-69.
60. Fiorentini C, Busi C, Spano P, Missale C, (2010) Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. Curr Opin Pharmacol 10: 87-92.
61. Surmeier DJ, Song WJ, Yan Z, (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16: 6579-6591.
62. Le Moine C, Bloch B, (1996) Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience 73: 131-143.
63. Ridray S, Griffon N, Mignon V, Souil E, Carboni S, et al. (1998) Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. Eur J Neurosci 10: 1676-1686.
64. Schwartz JC, Diaz J, Bordet R, Griffon N, Perachon S, et al. (1998) Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Res Brain Res Rev 26: 236-242.
65. Bordet R, Ridray S, Schwartz JC, Sokoloff P, (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12: 2117-2123.
66. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, et al. (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411: 86-89.
67. Zeng C, Wang Z, Li H, Yu P, Zheng S, et al. (2006) D3 dopamine receptor directly interacts with D1 dopamine receptor in immortalized renal proximal tubule cells. Hypertension 47: 573-579.
68. Marcellino D, Ferre S, Casado V, Cortes A, Le Foll B, et al. (2008) Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283: 26016-26025.
69. Canfield DR, Spealman RD, Kaufman MJ, Madras BK, (1990) Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain. Synapse 6: 189-195.
70. De La Garza R 2nd, Meltzer PC, Madras BK, (1999) Non-amine dopamine transporter probe [(3)H]tropoxene distributes to dopamine-rich regions of monkey brain. Synapse 34: 20-27.
71. Kaufman MJ, Spealman RD, Madras BK, (1991) Distribution of cocaine recognition sites in monkey brain: I. In vitro autoradiography with [3H]CFT. Synapse 9: 177-187.
72. Scherman D, Raisman R, Ploska A, Agid Y, (1988) [3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 50: 1131-1136.
73. Tian L, Karimi M, Loftin SK, Brown CA, Xia H, et al. (2012) No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 7: e31439.
74. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, et al. (2003) Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 87: 574-585.
75. Troiano AR, Schulzer M, de la Fuente-Fernandez R, Mak E, McKenzie J, et al. (2010) Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 64: 146-151.
76. Yue F, Zeng S, Wu D, Yi D, Alex Zhang Y, et al. (2012) Age-related decline in motor behavior and striatal dopamine transporter in cynomolgus monkeys. J Neural Transm.
77. Cortes R, Gueye B, Pazos A, Probst A, Palacios JM, (1989) Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience 28: 263-273.
78. Jucaite A, Forssberg H, Karlsson P, Halldin C, Farde L, (2010) Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study. Neuroscience 167: 104-110.
79. Wang Y, Chan GL, Holden JE, Dobko T, Mak E, et al. (1998) Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 30: 56-61.
80. Inoue M, Suhara T, Sudo Y, Okubo Y, Yasuno F, et al. (2001) Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci 69: 1079-1084.
81. Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, et al. (2000) Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 54: 1482-1487.
82. Rinne JO, Hietala J, Ruotsalainen U, Sako E, Laihinen A, et al. (1993) Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. J Cereb Blood Flow Metab 13: 310-314.